Q4 2025 Earnings Call February 12, 2026 8:00 AM ESTCompany ParticipantsGiuseppe Di Salvo - VP of Investor Relations ...
Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results